Background {#Sec1}
==========

*Staphylococcus aureus* is a recognized cause of mild to severe infections worldwide \[[@CR1], [@CR2]\]. However, the burden due to staphylococcal infections in Africa is apparently overshadowed by the 'big three' diseases --HIV/AIDS, tuberculosis and malaria \[[@CR3], [@CR4]\]. Indeed, surveillance studies on bacterial infections in Africa show that *S. aureus* is a common pathogen in healthy adults and immunosuppressed individuals \[[@CR3]--[@CR12]\], and persons with genetic predispositions \[[@CR10]\]. As well, *S. aureus* is second only to the pneumococcus among the frequent causes of pneumonia in children in Africa \[[@CR13]\].

Methicillin resistant *S. aureus* (MRSA) strains, now widespread globally, have complicated treatment and control of staphylococcal infections. Once confined to hospitals and/or health care environments, MRSA strains are now frequent causes of infection in the community. Nevertheless, surveillance studies have revealed differences in MRSA strains causing infections in hospitalized patients and healthcare workers in hospitals vis-à-vis MRSA isolates causing infection in the community (i.e. community-associated MRSA) \[[@CR1], [@CR2], [@CR14]\]. While such demarcation of MRSA as "hospital/health care-associated MRSA" (HA-MRSA) or "community-associated MRSA" (CA-MRSA) can be confusing \[[@CR1], [@CR14]--[@CR16]\], there are clear differences in phenotypes and genetic background of MRSA strains associated with infection in either setting, community or hospital \[[@CR1], [@CR2], [@CR14], [@CR17], [@CR18]\]. Genotypically, CA-MRSA are newer and more virulent strains, which emerged in the late 1990s as major causes of skin and soft tissue infections in healthy and relatively young people with no prior exposure to hospitals \[[@CR1], [@CR2], [@CR19], [@CR20]\]. CA-MRSA strains typically carry SCC*mec* types IV or V and they are generally susceptible to non-β-lactam antimicrobials \[[@CR1], [@CR2], [@CR14]\]. Additionally, CA-MRSA carry (but not always) Panton Valentine Leukocidin (PVL) encoding genes *LukS-PV* and *LukF-PV* \[[@CR1], [@CR2]\] that are associated with increased virulence. On the other hand, HA-MRSA strains carry SCC*mec* types I, II, or III and seldom possess PVL-encoding genes \[[@CR1], [@CR2]\]. HA-MRSA are associated with nosocomial infections e.g. endocarditis and they are often resistant to non-β-lactam antimicrobial agents especially aminoglycosides, macrolides, lincosamides and fluoroquinolones \[[@CR1], [@CR2]\].

Although CA-MRSA has been predicted to replace HA-MRSA in hospitals \[[@CR19]\], mathematical models predict coexistence between the two strains given the high rates of discharge and hospitalization which bolster hospital-community interactions \[[@CR21]\]. Relatedly, we previously detected MRSA strains carrying SCC*mec* types IV or V at Mulago Hospital in Kampala city \[[@CR22], [@CR23]\], pointing to coexistence between CA-MRSA and HA-MRSA in the hospital. The aim of this study was to determine the MRSA carriage rate in children in eastern Uganda, and to investigate coexistence between CA-MRSA and HA-MRSA.

Methods {#Sec2}
=======

Study setting, susceptibility testing and MRSA identification {#Sec3}
-------------------------------------------------------------

This cross-sectional study was nested in a study that investigated pneumococcal carriage in children under 5 years age in the Iganga/Mayuge Health & Demographic Surveillance Site (IMHDSS) \[[@CR13]\], located in Iganga and Mayuge districts in eastern Uganda 120 km from Kampala city, Uganda's capital. The IMHDSS is a rural community covering a contiguous area of \~ 155 km^2^ comprising of 65 villages and approx. 85,000 people living in 15,652 households. It is characterized with significant interaction between healthcare workers and community members, and 13% of its population are children under 5 years of age \[[@CR24]\].

The children screened for MRSA carriage were from a total of 742 households (one child per household). They were selected from the IMHDSS population register using simple random sampling. Each household was visited and a child aged between 2 months and 59 months was selected using the lottery method of sampling. Using a pretested questionnaire, the primary caretaker of the child in each household was interviewed for information on demographic characteristics, history of illnesses and antibiotic treatment. Following caretaker consent, a nasopharyngeal sample from each child was collected by a study nurse using pre-packed sterile calcium alginate swabs on flexible aluminum shafts (Becton, Dickson and Company, New Jersey). Swabs were placed in Amies transport medium in a tube and transported to the Clinical Microbiology laboratory at Makerere University College of Health Sciences where they were processed for culturing and isolation/identification of *S. aureus* according to standard microbiological procedures published previously \[[@CR25]\].

Susceptibility of *S. aureus* to antibiotics was determined by the disc diffusion antibiotic sensitivity testing method as recommended by the Clinical and Laboratory Standards Institute, (CLSI, 2011) \[[@CR26]\]. Briefly, colonies of pure bacterial isolates were suspended in sterile normal saline to a turbidity of McFarland standard 0.5, and uniformly spread on Muller Hinton agar (MHA) plates (Biolabs®, Hungary) with antibiotic disks (Biolabs®, Hungary): penicillin G (10 U), cefoxitin (30 μg), clindamycin (2 μg), erythromycin (15 μg), vancomycin (30 μg), tetracycline (30 μg), linezolid (30 μg), trimethoprim/sulphamethoxazole (1.25/23.5 μg), chloramphenicol (5 μg), ciprofloxacin (5 μg), and gentamicin (10 μg). Plates were incubated at 37 °C for 24 h. Inhibition zones were measured in millimeters and interpreted as susceptible (S), intermediate (I) or resistant (R). *S. aureus* with inhibition zone diameters of ≤19 mm on 30 μg cefoxitin disk were considered to be MRSA, and confirmed for *mecA* gene carriage by PCR \[[@CR1], [@CR22]\].

Classification of isolates as CA-MRSA or HA-MRSA {#Sec4}
------------------------------------------------

Because CA-MRSA and HA-MRSA can be recovered from either setting (i.e. community or hospital), to classify isolates as CA-MRSA or HA-MRSA we used isolate genotypic characteristics and not clinical/epidemiological features. Thus, given that SCC*mec* types I, II & III are typically restricted to HA-MRSA and not found widely in healthy populations while SCC*mec* types IV & V are predominantly associated with CA-MRSA \[[@CR1], [@CR2], [@CR18], [@CR19], [@CR21], [@CR27]\], MRSA isolates that carried SCC*mec* types I, II, or III were classified as HA-MRSA while isolates with SCC*mec* types IV or V were classified as CA-MRSA \[[@CR28]\]. SCC*mec* genotyping to delineate HA-MRSA and CA-MRSA was performed as described by Boye, et al., (2007) \[[@CR29]\]. Also, we compared SCC*mec* types for MRSA isolates from the IMHDSS in eastern Uganda to previously described SCC*mec* types for MRSA isolates from Mulago Hospital in Kampala \[[@CR22], [@CR23]\] and pastoral communities in rural western Uganda \[[@CR30], [@CR31]\]. Coexistence between HA-MRSA and CA-MRSA in the community or hospital was based on occurrence of MRSA strains with genetic background of both HA-MRSA (i.e. SCC*mec* types I, II or III) and CA-MRSA (i.e. SCC*mec* types IV or V) in either setting.

Spa typing {#Sec5}
----------

For spa typing, the *x*-region (200--400 bp) of *S. aureus spa* gene was amplified from MRSA with primers and PCR conditions described by Harmsen et al., 2003 \[[@CR32]\]. Purified PCR products were sequenced at MBN Laboratories (Kampala, Uganda) or ACGT Inc. (Wheeling, IL, USA) using forward and reverse primers used in PCRs. To obtain *spa* types, sequences were submitted to an online spaTyper server (<http://spatyper.fortinbras.us/>) and confirmed by cross-checking with Ridom Spa Server (<http://spaserver2.ridom.de/spatypes.shtml>). For quality control, standard reference *S. aureus* strains ATCC-43300 -*mecA*+, PVL- (MRSA) and ATCC-29213 -mecA-, PVL- (MSSA) & ATCC-25923 -*mecA*-, PVL+ (MSSA) were used as positive or negative controls. Furthermore, to detect *PVL* genes, isolates were subjected to PCR-detection of a 433 bp fragment overlapping the *lukS-PV* and *lukF-PV* genes using previously published protocols \[[@CR22], [@CR23]\]. Apart from *spa* typing in which all PCR products were sequenced, DNA sequencing of amplified segments of *mecA* and *PVL* genes for randomly selected isolates was performed and sequences confirmed by BLAST searching at the National Center for Biotechnology Information (NCBI) <https://blast.ncbi.nlm.nih.gov/Blast.cgi>

Results {#Sec6}
=======

Demographics {#Sec7}
------------

MRSA isolates were recovered from 42 of the 742 children sampled. The characteristics of study population were described previously \[[@CR13]\] however, we will highlight a few statistics pertinent to this study. The mean age of the children was 30 months and 52% were girls. All children were healthy at the time of screening i.e. none had observable clinical symptoms however, based on reports of caretakers (mothers), majority (≥90%) were sick 2 weeks prior to screening and the most common symptoms were fever, running nose and cough. Approx. 30% of the previously sick children were given antibiotics, mostly ampicillin and co-trimoxazole.

MRSA prevalence and drug resistance patterns {#Sec8}
--------------------------------------------

The processed nasopharyngeal samples yielded 600 Gram positive and catalase positive isolates (one per sample/child) of which 140 were confirmed to be *S. aureus*. Thirty per cent (42/140) of *S. aureus* were cefoxitin resistant and these were confirmed to be MRSA upon *mecA* gene PCR (all 42 isolates were *mecA* positive). Thus, MRSA prevalence in *S. aureus* isolates was 30% and its carriage rate in children was 5.7% (42/742). Almost all MRSA isolates i.e. 95.2% (40/42) were multidrug resistant (MDR, resistance to three or more classes of antimicrobials) and MDR rates for CA-MRSA and HA-MRSA isolates were similar, Table [1](#Tab1){ref-type="table"}. All MRSA isolates were susceptible to rifampicin and anti-MRSA agents (vancomycin & linezolid) and generally to clindamycin but they were significantly resistant to non-β-lactam antimicrobial agents commonly used to treat staphylococcal infections (SXT, erythromycin, gentamicin, chloramphenicol).Table 1Genotypes and antibiotic susceptibility patterns of CA- & HA-MRSA from children ≤5 years in eastern UgandaIsolate \#PVL*mecA*SCC*mec*FOXPENTETERYSXTCHLGENCIPCLIRIFVANLZDMDR phenotype*Spa* typeHA-MRSA (*n* = 21) 52--1++IRRRRRRRSSSSSYes 1320--1--+IRRRRRRRRSSSSYes 244C-1--+IRRRRRRRSSSSSYes K1057--1--+IRRRSSRRSSSSSYes**t037** K264--1++IRRRSSRRSSSSSYes K284--1--+IRRRRRRRSSSSSYes K36--1--+IRRRRRRSSSSSSYes**t037** K370--1--+IRRRRRRRSSSSSYes K39--1--+IRRRRRRRRSSSSYes K4834--1--+IRRRSSRRSSSSSYes**t037** K970--1--+IRRRSISSISSSSNo**t037** R030--1--+IRRRRRRRRSSSSYes R10--1--+IRRRRRRSRSSSSYest12939 R110--1++IRRRRRSSSSSSSYesUnknown R19--1--+IRRRRRRRSSSSSYes R220--1--+IRRRRRSRSSSSSYesUnknown 1322--1++IIRRRRRRRIISSSYes 306C-1--+IIRRRRRIRSSSSSYes K911--1--+IIRRRRSRRRSSSSYes R160--1--+IIRRRRRSSSSSSSYest002 R17--1--+IIIRRRSRSISSSSSYes**t037** Total +/R HA-MRSA (%)4 (19)21 (100)21 (100)21 (100)21 (100)21 (100)16 (76.2)16 (76.2)15 (71.4)15 (71.4)5 (23.8)0 (0)0 (0)0 (0)0 (0)20 (95.2)CA-MRSA (*n* = 21) 1325--1--+IVRRRRRRISSSSSYesUnknown 1326--1++IVRRRRSSSRSSSSYes K2240--1--+IVRRSSSSSRISSSNot4353 K2810--1--+IVRRRRRSSRSSSSYes R31B-1--+IVRRRRRSRRSSSSYes**t064** R310--1--+IVRRRRRRRSSSSSYes**t064** R33--1++IVRRRRRRRSSSSSYes**t064** K3700--1--+IVRRRSSRRSSSSSYes R0100--1--+IVRRRRRSSSSSSSYes**t064** R02--1--+IVRRRRRRSRSSSSYesUnknown R020--1--+IVRRSSRRRSSSSSYes R0300--1--+IVRRRRRRSSSSSSYes R06--1--+IVRRRRRSRSSSSSYes**t064** R08--1++IVRRRRRRRSSSSSYes**t064** R18--1--+IVRRRRSRSRSSSSYes R20--1--+IVRRIRRRRSSSSSYes**t064** R26A-1--+IVRRRRRSSRSSSSYes**t064** R040--1--+VRRRRRRRRSSSSYes K60--1++VRRRRRSSRSSSSYes K38--1--+VRRRRRRRISSSSYes K350C-1++VRRRSSSSRSSSSYesUnknown Total +/R CA-MRSA (%)5 (24)21 (100)21 (100)21 (100)21 (100)18 (85.7)17 (81)16 (76.2)12 (57.1)10 (47.6)10 (47.6)0 (0)0 (0)0 (0)0 (0)20 (95.2)**Grand Total +/R (%)9 (21.4)**42 (100)42 (100)**42 (100)42 (100)39 (92.9)33 (78.6)32 (76.2)27 (64.3)25 (59.5)15 (35.7)0 (0)0 (0)0 (0)0 (0)40/42 (95.2)**The most prevalent Spa types are presented in boldface font*FOX* cefoxitin, *PEN* penicillin, *TET* tetracycline, *SXT*, *ERY* erythromycin, *CHL* chloramphenicol, *GEN* gentamycin, *CIP* ciprofloxacin, *CLI* clindamycin, *RIF* rifampicin, *VAN* vancomycin, *LZD* linezolid, *MDR* multidrug resistant --resistance to three or more classes of antimicrobials; *+* Positive, − Negative

Spa types and SCC*mec* elements {#Sec9}
-------------------------------

The most predominant SCC*mec* elements were SCC*mec* type IV (40.5%, 17/42) and SCC*mec* type I (38.1%, 16/42). SCC*mec* types II and V accounted for 4 isolates each (9.5%, 4/42) while SCC*mec* type III accounted for one isolate. The overall frequency of SCC*mec* types IV and V combined, which define the genetic background of MRSA isolates associated with the community, was 50% (21/42) implying the prevalence of CA-MRSA in children was 50% (21/42). This is relatively low compared to reported rates of CA-MRSA in the community. Furthermore, the overall frequency of SCC*mec* types I, II and III combined, which define the genetic trait of MRSA isolates associated with healthcare environments, was 50% (21/42) hence similar to SCC*mec* types IV and IV combined. The *PVL* gene prevalence was low (i.e. 21.4%, 9/42) and distributed equally in CA-MRSA and HA-MRSA, Table [1](#Tab1){ref-type="table"}. Taken together, these data show that CA-MRSA and HA-MRSA coexist in children in the community in eastern Uganda, Table [1](#Tab1){ref-type="table"} & Fig. [1](#Fig1){ref-type="fig"}.Fig. 1SCCmec types for MRSA isolates depicting coexistence between CA-MRSA and HA-MRSA in children under 5 years in rural eastern Uganda. Note that the categorization of MRSA isolates as CA-MRSA or HA-MRSA is based on their genetic background (i.e. SCC*mec* types) and not clinical/epidemiological associations. MH denotes Mulago National Referral Hospital; IMHDSS, Health & Demographic Surveillance Site; RWU, Rural Western Uganda

The observed coexistence between CA-MRSA and HA-MRSA in Uganda was first reported at Mulago Hospital in Kampala \[[@CR22], [@CR23]\] but not explored further. Therefore, we compared previously reported SCC*mec* types for isolates at Mulago Hospital \[[@CR22], [@CR23]\] and pastoral communities in western Uganda \[[@CR30], [@CR31]\] with SCC*mec* types for isolates from IMHDSS. Due to frequent interactions between healthcare personnel from the Mulago Hospital setting and community members in IMHDSS, we hypothesized that the SCC*mec* types' distribution in the two settings would be similar. Indeed, there was no statistical significance (*P* = 0.1014) in the distribution of SCC*mec* types between the IMHSS and Mulago Hospital (Fig. [1](#Fig1){ref-type="fig"}) hence, CA-MRSA and HA-MRSA coexist in IMHDSS (community) and Mulago Hospital. Conversely, MRSA from pastoral communities in rural western Uganda carried only SCC*mec* types IV and V, Fig. [1](#Fig1){ref-type="fig"}.

A total of five genotypes (t002, t037, t064, t4353 and t12939) were detected among MRSA and the most predominant were t064 (19%, 8/42) and t037 (12%, 5/42). Thus, t064 and t037 are the prevalent spa types among CA-MRSA and HA-MRSA isolates respectively, Table [1](#Tab1){ref-type="table"} & Additional file [1](#MOESM1){ref-type="media"}: Figure S1. When we compared *spa* types with MRSA isolates from Mulago Hospital \[[@CR22], [@CR23]\] and pastoral communities in rural western Uganda \[[@CR30], [@CR31]\], we found that with the exception of t002 and t12939, spa types for MRSA isolates from IMHDSS were previously reported, Additional file [1](#MOESM1){ref-type="media"}: Figure S1. There were subtle differences in distribution of *spa* types with respect to setting e.g. *spa* types restricted to pastoral communities in rural western Uganda (circled in Additional file [1](#MOESM1){ref-type="media"}: Figure S1).

Discussion {#Sec10}
==========

In this study, we found the MRSA carriage rate (5.7%) in children in eastern Uganda to be high and comparable to reported estimates for MRSA prevalence in adult populations in Uganda \[[@CR7], [@CR9], [@CR23]\] and generally East Africa \[[@CR33], [@CR34]\]. Furthermore, we have shown that CA-MRSA and HA-MRSA strains coexist in the community in eastern Uganda and at Mulago hospital in Kampala city. Coexistence between CA-MRSA and HA-MRSA has been reported extensively in developed countries \[[@CR16], [@CR35]--[@CR38]\] and beyond \[[@CR35], [@CR39]--[@CR42]\] but few studies in Africa have explored it. Note, the terms 'CA-MRSA' and 'HA-MRSA' have also been used to describe the epidemiological and clinical features of MRSA e.g. the CDC case definition for CA-MRSA infection "Any MRSA infection diagnosed for an outpatient or within 48 h of hospitalization if the patient lacks the following health care-associated MRSA risk factors: hemodialysis, surgery, residence in a long-term care facility or hospitalization during the previous year, the presence of an indwelling catheter or a percutaneous device at the time of culture" \[[@CR1]\], but such epidemiological/clinical definitions are also misleading \[[@CR1], [@CR14], [@CR21]\]. While there is no consensus on interpretation of 'HA-MRSA vs. CA-MRSA', MRSA strains are genotypically distinguishable through a simple PCR assay, SCCmec typing. Currently there are nine SCC*mec* types --I, II, III, IVa, IVb, V, VI, VII, VIII and V~T~ \[[@CR1]\]; types I, II and III are large and occur in HA-MRSA strains while types IV and V are smaller and occur in CA-MRSA strains \[[@CR1], [@CR2], [@CR21]\].

There are several factors that could be fuelling coexistence between CA-MRSA and HA-MRSA in the community in eastern Uganda. First, previous exposure to antibiotics and/or health care facilities as the children were reported to be previously sick. The mothers reported that about one third of the children had been given ampicillin and co-trimoxazole and this could explain the high prevalence of MRSA and SXT resistance detected. It is important to note that over-treatment of children with antibiotics is common in Uganda as children suffer from 0.3 episodes of pneumonia every year \[[@CR13]\]. Also, Uganda adopted the World Health Organization's (WHO) integrated case management of childhood illnesses under which community health workers provide prompt treatment of malaria and bacterial infections for children less than 5 years of age. The WHO's integrated case management guidelines are based on simple clinical signs to help health workers identify and manage malaria, pneumonia and other childhood illnesses in the community. Although they have been found to increase rational prescription of medicines, the WHO guidelines do not distinguish between viral, parasitic (excluding plasmodium) and bacterial infections implying that a significant number of children in the community receive antibiotics \[[@CR13]\]. Thus, some MRSA strains in IMHDSS were indeed HA-MRSA perhaps arising from circulation of "escaped"/"feral" HA-MRSA strains in the community as a consequence of management of childhood infections at home \[[@CR1]\].

The second factor underlying coexistence of CA-MRSA and HA-MRSA in children in eastern Uganda and generally at Mulago Hospital could be the interaction between healthcare workers and community members. Mathematical models of MRSA transmission have predicted that Hospital-Community interactions foster coexistence between CA-MRSA and HA-MRSA strains as the high discharge and hospitalization rates continuously cycle individuals between hospitals and the community \[[@CR21]\]. Besides, other investigators have implicated frequent interaction between healthcare workers and community members in increasing the risk of colonization with MRSA in the community \[[@CR17]\]. In Uganda, medical students, faculty, health care workers and researchers from the Mulago Hospital setting which includes Makerere University medical school use the IMHDSS as a site for disease surveillance, research and community-based medical education. The IMHDSS community members could also be colonized by HA-MRSA from nearby healthcare facilities as the IMHDSS is served by a government hospital, nine public health centers, three non-governmental organization hospitals, 122 drug shops and private clinics \[[@CR24]\]. Furthermore, studies by Asiimwe et al. \[[@CR30], [@CR31]\] on MRSA carriage in pastoral communities in rural western Uganda provided additional support for coexistence between CA-MRSA and HA-MRSA in the IMHDSS and Mulago Hospital. MRSA isolates from pastoral communities in rural western Uganda carried only SCC*mec* types IV and V that are typical of CA-MRSA and SCC*mec* types I, II and III were not detected \[[@CR30], [@CR31]\] hence, CA-MRSA and HA-MRSA do not coexist in pastoral communities in rural western Uganda. In context of health service delivery in Uganda, this is understandable as pastoral communities are remote and often characterized with inadequate health service delivery.

Almost all MRSA isolates in this study were MDR. As HA-MRSA strains are associated with multiple resistance to non-β-lactam antimicrobial agents, perhaps their prevalence contributed to the observed high resistance to non-β-lactam antimicrobials. On the other hand, CA-MRSA strains are usually susceptible to non-β-lactam antimicrobials \[[@CR1], [@CR2]\] but in this study they were not. One explanation for the MDR phenotype and high resistance to non-β-lactam antimicrobials among CA-MRSA could be acquisition of drug resistance genes \[[@CR27]\]. A similar trend of CA-MRSA being MDR has been observed elsewhere especially in Europe, Asia and the Americas \[[@CR43]--[@CR46]\]. Case in point is a study from a large veterinary teaching hospital in Costa Rica where nearly all CA-MRSA isolates investigated were MDR and carried SCC*mec* type IV \[[@CR44]\].

Lastly, this study had a few limitations. First, the small number of MRSA isolates investigated implies that differences observed could be due to low frequencies of genotypes recorded. However, we sampled a larger population for recovery of MRSA compared to previous studies in Uganda \[[@CR7], [@CR9], [@CR22], [@CR23]\]. Second, for reasons already explained, we used isolate genotypic characteristics to classify MRSA isolates as our interest was in unambiguously identifying CA-MRSA and HA-MRSA. While important, clinical/epidemiological features were not considered as both CA-MRSA and HA-MRSA may occur in either setting i.e. community or hospital \[[@CR14], [@CR21]\].

Conclusions {#Sec11}
===========

The MRSA carriage rate in children in rural eastern Uganda is high (5.7%) and comparable to estimates for a large urban teaching facility, Mulago National Referral Hospital, located in Uganda's capital, Kampala. Importantly, HA-MRSA (mainly of *spa* type t037) and CA-MRSA (mainly of *spa* type t064) coexist in community and hospital settings in Uganda with no statistical significance for observed differences in rates. Because interaction between healthcare workers and community members contributes to presence of HA-MRSA in the community, standard hygiene measures should be reinforced to prevent cross-transmission at the IMHDSS. As well, due to the high proportion of MDR-MRSA detected, outpatient treatment of MRSA infections in eastern Uganda might be difficult.

Additional file
===============

 {#Sec12}

Additional file 1:**Figure S1.** *Spa* types for MRSA isolates from children under 5 years in rural eastern Uganda. MH denotes Mulago National Referral Hospital; IMHDSS, Health & Demographic Surveillance Site; RWU, Rural Western Uganda. The circle signifies *spa* types that appear restricted to rural western Uganda. (TIFF 3173 kb)
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